Lymphocyte-rich classical hodgkin's lymphoma: Distinctive tumor and microenvironment markers

Modern Pathology

Volumn 22, Issue 8, 2009, Pages 1006-1015

  Nam Cha, Syong H ^a,b   Montes Moreno, Santiago ^b   Salcedo, Maria T ^c   Sanjuan, Josefina ^d   Garcia, Juan F ^b,e   Piris, Miguel A ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Lymphocyte rich classical Hodgkin's lymphoma; T cell microenviroment

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD23 ANTIGEN; CD3 ANTIGEN; CD57 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CXCL13 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN BCL 6; PROTEIN P50; PROTEIN PD 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BOB 1; TRANSCRIPTION FACTOR GCET1; TRANSCRIPTION FACTOR KLHL6; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MICROENVIRONMENT; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL;

B-LYMPHOCYTES; FLUORESCENT ANTIBODY TECHNIQUE; GERMINAL CENTER; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; NF-KAPPA B; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68249112538     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.54     Document Type: Article

References (22)

1. Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon, Washington, DC, 2001.
2. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005;23:5739-5745.
3. Brauninger A, Wacker HH, Rajewsky K, et al. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res 2003;63:1644-1651.
4. Garcia-Cosio M, Santon A, Martin P, et al. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol 2004;17:1531-1538.
5. Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007;92:1059-1066.
6. Mason DY, Micklem K, Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 2000;191:452-461.
7. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-783.
8. Ashton-Key M, Thorpe PA, Allen JP, et al. Follicular Hodgkin's disease. Am J Surg Pathol 1995;19: 1294-1299.
9. de Jong D, Bosq J, MacLennan KA, et al. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Ann Oncol 2006;17:141-145.
10. Kroll J, Shi X, Caprioli A, et al. The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation. Mol Cell Biol 2005;25:8531-8540.
11. Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood 2008;111: 351-358.
12. Chan WC. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999;36: 242-252.
13. Hinz M, Loser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001;97:2798-2807.
14. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 2001;14:297-310.
15. Xiao Q, Shen N, Hedvat CV, et al. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2004;12:211-215.
16. Rodig SJ, Savage KJ, Nguyen V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005;29: 196-203.
17. Nam-Cha SH, Roncador G, Sanchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008;32:1252-1257.
18. Vinuesa CG, Tangye SG, Moser B, et al. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005;5:853-865.
19. Kraus MD, Haley J. Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000;24:1068-1078.
20. Hardie DL, Johnson GD, Khan M, et al. Quantitative analysis of molecules which distinguish functional compartments within germinal centers. Eur J Immunol 1993;23:997-1004.
21. Hauser AE, Junt T, Mempel TR, et al. Definition of germinal-center B cell migration in vivo reveals predominant intrazonal circulation patterns. Immunity 2007;26:655-667.
22. Brink R. Germinal-center B cells in the zone. Immunity 2007;26:552-554.